Two-year survival outcomes after matched-pair analysis in subgroups of patients
| . | LFS (95% CI) . | OS (95% CI) . | GRFS (95% CI) . | RI (95% CI) . | NRM (95% CI) . |
|---|---|---|---|---|---|
| Patients receiving cyclosporine + mycophenolate mofetil | |||||
| PTCY | 58 (41-76) | 59 (41-77) | 40 (19-60) | 31 (15-48) | 11 (3-23) |
| ATG | 29 (19-39) | 33 (22-43) | 14 (6-22) | 38 (27-49) | 33 (22-43) |
| P | .08 | .12 | <.02 | .52 | .07 |
| Patients in CR at time of transplant | |||||
| PTCY | 63 (50-77) | 63 (48-78) | 41 (26-56) | 22 (12-34) | 14 (6-26) |
| ATG | 42 (33-52) | 45 (35-54) | 25 (16-34) | 30 (22-39) | 27 (19-36) |
| P | .04 | <.05 | <.05 | .29 | .13 |
| Patients receiving PB as stem cell source | |||||
| PTCY | 57 (45-69) | 60 (48-72) | 37 (24-50) | 29 (19-40) | 14 (7-24) |
| ATG | 34 (26-43) | 38 (30-47) | 23 (15-30) | 37 (29-45) | 28 (21-36) |
| P | .03 | .04 | .03 | .482 | .04 |
| . | LFS (95% CI) . | OS (95% CI) . | GRFS (95% CI) . | RI (95% CI) . | NRM (95% CI) . |
|---|---|---|---|---|---|
| Patients receiving cyclosporine + mycophenolate mofetil | |||||
| PTCY | 58 (41-76) | 59 (41-77) | 40 (19-60) | 31 (15-48) | 11 (3-23) |
| ATG | 29 (19-39) | 33 (22-43) | 14 (6-22) | 38 (27-49) | 33 (22-43) |
| P | .08 | .12 | <.02 | .52 | .07 |
| Patients in CR at time of transplant | |||||
| PTCY | 63 (50-77) | 63 (48-78) | 41 (26-56) | 22 (12-34) | 14 (6-26) |
| ATG | 42 (33-52) | 45 (35-54) | 25 (16-34) | 30 (22-39) | 27 (19-36) |
| P | .04 | <.05 | <.05 | .29 | .13 |
| Patients receiving PB as stem cell source | |||||
| PTCY | 57 (45-69) | 60 (48-72) | 37 (24-50) | 29 (19-40) | 14 (7-24) |
| ATG | 34 (26-43) | 38 (30-47) | 23 (15-30) | 37 (29-45) | 28 (21-36) |
| P | .03 | .04 | .03 | .482 | .04 |